title: 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
abstract: The tumor suppressor p53 is often referred to as "the guardian of the genome" because of its central role in the cellular response to oncogenic stress and prevention of tumor development. Mutations of p53 in acute myeloid leukemia (AML) are rare but resistance to chemotherapy has been reported because of the deregulation of the p53 signaling and differentiation pathways. It is known that the interaction of the vitamin D metabolite 1,25-dihydroxyvitamin D(3) (1,25D) with its functional vitamin D receptor leads to differentiation, G(1) arrest, and increased cell survival in p53-null AML cells. However, there are no reports on the effect of 1,25D in leukemia cells expressing wild-type p53. Here, we examine vitamin D signaling in AML cells MOLM-13 and OCI-AML3 expressing wild-type p53 in the presence and absence of the MDM2 antagonist nutlin-3. We find that 1,25D alone induces monocytic differentiation in these cell lines similar to that seen in p53-null AML cells, suggesting that the presence of wild-type p53 is compatible with activation of vitamin D signaling. Combination of nutlin-3a with 1,25D accelerated programmed cell death, likely because of enhanced nutlin-induced upregulation of the proapoptotic PIG-6 protein and downregulation of antiapoptotic BCL-2, MDMX, human kinase suppressor of Ras 2, and phosphorylated extracellular signal-regulated kinase 2.
authors.affiliation: Discovery Oncology, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, New Jersey, USA.
authors.forename: Thelma
authors.initials: T
authors.lastname: Thompson
authors.forename: Michael
authors.initials: M
authors.lastname: Andreeff
authors.forename: George P
authors.initials: GP
authors.lastname: Studzinski
authors.forename: Lyubomir T
authors.initials: LT
authors.lastname: Vassilev
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002117:Calcitriol / Q000008:administration & dosage / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D016158:Genes, p53; D018922:HL-60 Cells; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000494:pharmacology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009000:Monocytes / Q000187:drug effects / Q000502:physiology; D010879:Piperazines / Q000008:administration & dosage* / Q000494:pharmacology; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D007093:Imidazoles; D010879:Piperazines; C482205:nutlin 3; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D002117:Calcitriol
references.citation: Cancer Res. 2003 Mar 15;63(6):1325-32
references.pmid: 12649194
references.citation: Proc Soc Exp Biol Med. 1985 Jul;179(3):288-95
references.pmid: 3858884
references.citation: Endocr Rev. 1982 Fall;3(4):331-66
references.pmid: 6295752
references.citation: Blood. 1994 Jul 1;84(1):256-61
references.pmid: 8018920
references.citation: J Exp Med. 2006 Feb 20;203(2):371-81
references.pmid: 16446383
references.citation: J Clin Invest. 2001 Sep;108(6):851-9
references.pmid: 11560954
references.citation: Nature. 1997 Sep 18;389(6648):300-5
references.pmid: 9305847
references.citation: Cancer Res. 2001 Mar 1;61(5):1810-5
references.pmid: 11280728
references.citation: Cancer Res. 2007 Apr 1;67(7):3210-9
references.pmid: 17409429
references.citation: Blood. 1983 Oct;62(4):709-21
references.pmid: 6192859
references.citation: Mol Cancer Ther. 2008 Sep;7(9):3047-55
references.pmid: 18790784
references.citation: N Engl J Med. 1999 Sep 30;341(14):1051-62
references.pmid: 10502596
references.citation: Leukemia. 1997 Sep;11(9):1469-77
references.pmid: 9305600
references.citation: Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12792-6
references.pmid: 9371754
references.citation: Blood. 2005 Nov 1;106(9):3150-9
references.pmid: 16014563
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5000-5
references.pmid: 18698017
references.citation: Cancer Res. 2006 May 1;66(9):4574-83
references.pmid: 16651407
references.citation: J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):47-55
references.pmid: 16046262
references.citation: J Biol Chem. 2004 Dec 17;279(51):53015-22
references.pmid: 15471885
references.citation: Science. 2004 Feb 6;303(5659):844-8
references.pmid: 14704432
references.citation: Oncol Res. 2007;16(11):517-25
references.pmid: 18306931
references.citation: Leukemia. 2003 Jan;17(1):120-4
references.pmid: 12529668
references.citation: Cell Cycle. 2004 Jul;3(7):900-4
references.pmid: 15254433
references.citation: Hematol J. 2004;5(6):489-95
references.pmid: 15570290
references.citation: Trends Mol Med. 2007 Jan;13(1):23-31
references.pmid: 17126603
references.citation: Oncogene. 2006 Sep 14;25(41):5640-7
references.pmid: 16619034
references.citation: Cancer Res. 1985 Aug;45(8):3898-905
references.pmid: 3860289
references.citation: J Cell Physiol. 2006 Nov;209(2):253-60
references.pmid: 16883571
references.citation: Exp Cell Res. 2007 Aug 15;313(14):3034-45
references.pmid: 17599832
references.citation: Curr Top Med Chem. 2006;6(12):1267-71
references.pmid: 16848740
references.citation: Cell Cycle. 2008 Jun 1;7(11):1604-12
references.pmid: 18520179
references.citation: Cell Growth Differ. 2000 Nov;11(11):561-71
references.pmid: 11095245
references.citation: Oncogene. 1995 Mar 16;10(6):1053-9
references.pmid: 7700629
references.citation: Cell Cycle. 2004 Apr;3(4):419-21
references.pmid: 15004525
references.citation: Clin Exp Immunol. 1989 May;76(2):274-7
references.pmid: 2758696
references.citation: Cell. 1993 Aug 27;74(4):609-19
references.pmid: 8358790
references.citation: Int J Cancer. 2006 Jun 15;118(12):3012-21
references.pmid: 16395705
references.citation: Blood. 1994 Oct 15;84(8):2412-21
references.pmid: 7919360
references.citation: Leuk Lymphoma. 2000 Oct;39(3-4):257-70
references.pmid: 11342306
references.citation: Endocr Rev. 1995 Apr;16(2):200-57
references.pmid: 7781594
references.citation: Clin Cancer Res. 2001 Apr;7(4):1043-51
references.pmid: 11309356
references.citation: J Cell Biochem. 2001;80(4):471-82
references.pmid: 11169731
references.citation: Science. 2004 Feb 13;303(5660):1010-4
references.pmid: 14963330
references.citation: Cancer Res. 2004 Aug 1;64(15):5425-33
references.pmid: 15289351
references.citation: Oncogene. 1994 Nov;9(11):3397-406
references.pmid: 7936668
references.citation: J Cell Physiol. 2004 Mar;198(3):333-42
references.pmid: 14755538
references.citation: Nature. 1997 May 15;387(6630):296-9
references.pmid: 9153395
references.citation: Mol Cancer Ther. 2008 Sep;7(9):2798-806
references.pmid: 18790760
references.citation: Cancer Res. 1996 Jan 15;56(2):264-7
references.pmid: 8542578
references.citation: Oncogene. 1994 Jun;9(6):1799-805
references.pmid: 8183579